When will patent run out for trelegy?

When does the patent for Trelegy expire?

Trelegy is a brand name for a combination inhaler (fluticasone furoate/umeclidinium/vilanterol). Patent “run out” depends on which specific patent or exclusivity right you mean (a granted patent vs. other regulatory exclusivities), and on the country where you’re looking.

With the information provided here, I can’t determine the exact Trelegy patent expiration date because it requires checking the specific, relevant patents and their listed expiration dates.

What you should check to find the exact “run out” date

Searchers typically get the most accurate answer by checking:
- The expiration date of the key Trelegy formulation/device patents in the country of interest.
- Whether there are patent “term extensions” or additional listed patents that block generic/biosimilar entry.
- Any regulatory exclusivities tied to the product approval timeline.

A practical place to look up the specific patents and dates is DrugPatentWatch.com, which tracks patent-expiry information by product and market.
See: DrugPatentWatch.com – Trelegy

Can generics enter right after the last patent expires?

Even after the last listed patent expires, entry can still be delayed by:
- Additional later-expiring patents (so you need the full patent “family” list).
- Regulatory/market exclusivity periods that continue beyond the earliest patent date.
- Litigation that can affect launch timing.

If you tell me the country, I can narrow the answer

Patent timelines vary by jurisdiction (US vs EU vs UK, etc.). If you share which country you mean (for example, US or UK), I can help you pinpoint the relevant expiration date(s) you should look for.

Sources

1. DrugPatentWatch.com – Trelegy